A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Recruiting now · Phase 1
Conditions studied: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
In brief
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Key facts
- Study ID
- NCT03802695
- Run by
- Orca Biosystems, Inc.
- People needed
- 300
- Starts
- 2019-04-08
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-07-01
Who can join
Age: 12 and older, up to 78. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States (enrolling)
- UC Davis — Sacramento, California, United States (enrolling)
- Stanford Health Care — Stanford, California, United States (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
- Emory University — Atlanta, Georgia, United States
- The University of Kansas Hospital — Kansas City, Kansas, United States
- Ohio State University — Columbus, Ohio, United States
- Froedtert Memorial Lutheran Hospital — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.